scholarly journals Clear Cell Carcinoma Of The Ovary: An Experience From A Regional Cancer Centre In Odisha.

2021 ◽  
Vol 8 (11) ◽  
pp. 5822-5829
Author(s):  
Dr. Bhagyalaxmi Nayak ◽  
Dr. Neethu Sukesh ◽  
Dr. Manoranjan Mohapatra ◽  
Dr. Janmejay Mohapatra ◽  
Dr.Ashok Kumar Padhy ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Precancerous Lesions ◽  
Stage Iii ◽  
Cancer Centre ◽  
Regional Cancer Centre ◽  
Carcinoma Of The Ovary

Background: Clear cell carcinoma of the ovary (CCCO) shows unique clinical features. There is a remarkable difference in incidence among different ethnic  populations. The reasons for these differences in incidence around the world are not known. Aim and objectives: To evaluate the clinical characteristics of patients with CCCO and to determine the impact of the stage of the disease and the extent of surgery on the prognosis of those patients. Materials and methods: A retrospective analysis of the cases of clear cell carcinoma of the ovary that were operated in the regional cancer centre, Cuttack, from January 2009 to December 2018, was performed to evaluate the clinical characteristics and prognostic factors of the patients.  Results: During this study period, the incidence of CCCO was found to be 1.92%. The most common age group was 40–50 years (mean age of 44.7 years). The most common modes of presentation were abdominal distention and pain in the abdomen. Most of the cases in this study belonged to stage III C (65%), making it the most common stage in this group. 20% of the patients within the study group were nulliparous and 35% were menopausal in status.40% of the tumours were >15 cm in size. Almost 28% were lymph node positive. None in stage I had positive lymph nodes. All the cases in stage III were positive for lymph nodes. So, in stage III, 38.5% were positive for lymph nodes. 17/20 had some form of chemotherapy, of which 45% had NACT. Survival curves differ significantly between the early and advanced stages of the disease. A trend of survival benefit is seen with complete cytoreduction. Conclusion: There is a need for data regarding the incidence and specific clinicopathologic behaviour of clear cell carcinoma of the ovary in the Indian population. This is an attempt to compile the data from a single tertiary institute in eastern India over the past 10 years. This is a rare tumour and the chances of missing data are well accepted. The survival advantage of early-stage-diagnosed patients over late-stage patients is tremendous and hard to ignore. Combining the fact that clear cell carcinomas are associated with precancerous lesions like atypical endometriosis and atypical adenofibroma, there may be scope for screening. The mutational changes leading to malignancy in these precancerous lesions also need to be refined. As stated, complete cytoreduction is the key to survival advantage and the need for referral to a centre with proper expertise for the same needs to be emphasized.

scholarly journals The Clinical Characteristics and Treatment Results in the Patients with Clear Cell Carcinoma of the Ovary

2021 ◽  
Vol 4 (4) ◽  
pp. 01-08
Author(s):  
Chul Kim
Keyword(s):  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Figo Stage ◽  
Stage I ◽  
Stage Iii ◽  
Treatment Results ◽  
Platinum Based Chemotherapy ◽  
Carcinoma Of The Ovary

Background: It is well known that clear cell carcinoma of the ovary (CCC) demonstrates different clinical behaviors from other epithelial ovarian cancer and has strong association with endometriosis, thromboembolic complication, hypercalcemia, and large pelvic mass. The introduction of cisplatin-based chemotherapy significantly changed the postoperative management of ovarian cancer patients. Different studies showed a better response rate of CCC to chemotherapy with paclitaxel plus carboplatin regime than with the conventional platinum-based regimens. Aim: The purpose of this study was to evaluate the patients’ clinical characteristics and treatment results for clear cell carcinoma (CCC) of the ovary treated in paclitaxel-platinum chemotherapy in comparison with those treated in conventional platinum-based chemotherapy after primary surgery Methods: We retrospectively reviewed the medical records of 40 patients with CCC who received treatment in the department of obstetrics and gynecology, Samsung Medical Center from March, 1996 to April 2006. The clinical characteristics, treatment results and follow-up data were collected from medical records and/or telephone surveys. Results: Mean age was 47 years (range 30–72 years). Patients with age less than 50years were 62.5%. Tumors were 15% (6/40) stage IA, 2.5% (1/40) stage IB, 37.5% (15/40) stage IC, 5% (2/40) stage II, 32.5% (13/40) stage III, and 7.5% (3/40) stage IV. Patients with CCC were more likely to have FIGO stage I & II disease than FIGO stage III & IV (60% vs. 40%). Five-year progression-free survival and overall survival were 91% and 80% in stage I & II, 36% and 55% in stage III & IV, respectively (5-yr PFS; P<0.01, 5-yr OS; P=0.03). With a median follow-up of 45 months (2-112 months), 75% (18/24) of stage I/II patients are alive, while 19% (3/16) of stage III/IV patients are alive. 37.5% (15/40) of the patients presented with endometriosis. Except for one patient who was referred by a local clinic, all patients underwent cytoreductive surgery. The rate of optimal debulking (≤ 1cm residual tumor diameter) was 90% (36/40). Overall, for women treated with platinum-based chemotherapy, 75% (27/36) had clinically complete responses to adjuvant chemotherapy. But there was no survival benefit according to chemotherapeutic differences in the patients who received cytoreductive surgery followed between conventional platinum-based chemotherapy (CAP or CP) and by paclitaxel and platinum-based chemotherapy (P=0.40). Univariate analysis showed that stage was the only favorable prognostic factor for women with clear cell carcinoma of the ovary (P=0.04). Conclusions: Our results suggest that CCC has a distinct clinical behavior, similar to previous studies, that frequently presents at early- stages and is associated with endometriosis. In addition, there was a close correlation between the level of CA-125 and survival, and there was no survival benefit according to chemotherapeutic differences. 〔CAP (CP) VS TP(TC)〕

scholarly journals Clinical Characteristics and Prognosis of Ovarian Clear Cell Carcinoma: A 10-Year Retrospective Study

2020 ◽  
Author(s):  
Chenchen Zhu ◽  
Jing Zhu ◽  
Lili Qian ◽  
Hanyuan Liu ◽  
Zhen Shen ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Supporting Evidence ◽  
Ovarian Clear Cell Carcinoma ◽  
Positive Lymph Nodes

Abstract Background Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC), we conducted this research in order to investigate the clinical characteristics and outcomes of OCCC and to provide additional supporting evidence to aid in the clinical diagnosis and management. Methods This was a retrospective study investigating the clinical characteristics and survival outcomes of 87 patients with OCCC treated at our center between January 2010 and March 2020. Survival analysis was also performed on 179 patients with OCCC obtained from the Surveillance, Epidemiology and End Results (SEER) cancer registry database. Results The median age of participants was 49.28 ± 9.8 years old, with 74.71% diagnosed at early stage. Median CA125 level was 607.26 IU/mL, with 23.94% having normal CA125 levels. 16 patients (18.39%) had co-existing endometriosis and 8 patients (9.2%) developed venous thromboembolism (VTE). There were 5 patients received suboptimal cytoreduction. 67 patients (77.01%) underwent lymphadenectomy, and only 3 (4.48%) were found to have positive lymph nodes. Patients diagnosed at an early stage had higher 3-year overall survival (OS) and progression-free survival (PFS) rates than those with advanced stage OCCC. CA199 (P = 0.025) and ascites (P = 0.001) were significantly associated with OS, while HE4 (P = 0.027) and ascites (P = 0.001) were significantly associated with PFS. Analysis of data from the SEER database showed that positive lymph nodes is also an independent prognostic factor for OS (P = 0.001). Conclusions OCCC often presents at an early stage and young age with a mildly elevated CA125. CA199, HE4, massive ascites and positive lymph node are independent prognostic factors.

Clear Cell Carcinoma of the Ovary: A Distinct Histologic Type with Poor Prognosis and Resistance to Platinum-Based Chemotherapy in Stage III Disease

1996 ◽  
Vol 60 (3) ◽  
pp. 412-417 ◽  
Author(s):  
Barbara A. Goff ◽  
Ricardo Sainz de la Cuesta ◽  
Howard G. Muntz ◽  
Deborah Fleischhacker ◽  
Marit Ek ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Poor Prognosis ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Stage Iii ◽  
Histologic Type ◽  
Platinum Based Chemotherapy ◽  
Carcinoma Of The Ovary

scholarly journals Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chenchen Zhu ◽  
Jing Zhu ◽  
Lili Qian ◽  
Hanyuan Liu ◽  
Zhen Shen ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Supporting Evidence ◽  
Ovarian Clear Cell Carcinoma ◽  
Positive Lymph Nodes

Abstract Background Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC). We conducted this research to investigate the clinical characteristics and outcomes of OCCC and to provide additional supporting evidence to aid in the clinical diagnosis and management. Methods This was a retrospective study investigating the clinical characteristics and survival outcomes of 86 patients with OCCC treated at our center between January 2010 and March 2020. Survival analysis was also performed on 179 patients with OCCC obtained from the Surveillance, Epidemiology and End Results (SEER) cancer registry database. Results The median age of participants was 49.21 ± 9.91 years old, and 74.42% of them were diagnosed at early stage. The median CA125 level was 601.48 IU/mL, while 19.77% of the patients had normal CA125 levels. Sixteen patients (18.60%) had co-existing endometriosis and 8 patients (9.3%) developed venous thromboembolism (VTE). There were 5 patients received suboptimal cytoreduction. Sixty-six patients (76.74%) underwent lymphadenectomy, and only 3 (4.55%) patients had positive lymph nodes. Patients diagnosed at an early stage had higher 3-year overall survival (OS) and progression-free survival (PFS) rates than those with advanced stage OCCC. CA19–9 (P = 0.025) and ascites (P = 0.001) were significantly associated with OS, while HE4 (P = 0.027) and ascites (P = 0.001) were significantly associated with PFS. Analysis of data from the SEER database showed that positive lymph nodes is also an independent prognostic factor for OS (P = 0.001). Conclusions OCCC often presents at an early stage and young age with a mildly elevated CA125. CA19–9, HE4, massive ascites, and positive lymph node are independent prognostic factors.

scholarly journals Clinical characteristics of clear cell carcinoma of the ovary

Cancer ◽  
2000 ◽  
Vol 88 (11) ◽  
pp. 2584-2589 ◽  
Author(s):  
Toru Sugiyama ◽  
Toshiharu Kamura ◽  
Junzo Kigawa ◽  
Naoki Terakawa ◽  
Yoshihiro Kikuchi ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Carcinoma Of The Ovary

Clinical Characteristics of Clear Cell Carcinoma of the Ovary

1998 ◽  
Vol 70 (2) ◽  
pp. 255-258 ◽  
Author(s):  
Kian Behbakht ◽  
Thomas C. Randall ◽  
Ivor Benjamin ◽  
Mark A. Morgan ◽  
Stephanie King ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Carcinoma Of The Ovary

scholarly journals Age and Lymph Nodes Examination May Be Related to the Outcome of Ovarian Clear Cell Carcinoma: A SEER Analysis

2021 ◽  
Author(s):  
Menghan Zhu ◽  
Nan Jia ◽  
Wei Jiang
Keyword(s):  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Proportional Hazards ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Cox Proportional Hazards ◽  
Stage I ◽  
Stage Iii ◽  
Ovarian Clear Cell Carcinoma ◽  
Significant Difference

Abstract AimTo analyze and compare the demographics, treatment, and survival rates in patients with ovarian clear cell carcinoma (OCCC).MethodsWe conducted a population-based retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1998 to 2016. Data of 4344 women with OCCC were compared, and survival was analyzed using the Kaplan–Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model.ResultsThere was no significant difference in cause specific survival (CSS) regardless of chemotherapy in stage I and stage II OCCC. In women with stage III/IV OCCC, there was an increased mortality in women without chemotherapy (5-year CSS 29.80% vs. 24.90%, p<0.001). Among stage I women younger than 60 years old, the 5-year CSS of those underwent chemotherapy was worse than that of non-chemotherapy (86.4% vs. 97.50%, p=0.002). Among these patients, omitting chemotherapy had improved CSS (HR 0.539; 95% CI 0.386-0.753), and omitting lymph nodes examination had decreased CSS (HR 1.666; 95% CI 1.230-2.256). In stage III/IV women who were 60 years or older, the 5-year CSS of those underwent chemotherapy was better than that of non-chemotherapy (32.60% vs. 24.30%, p<0.001). Among these patients, omitting chemotherapy (HR 1.769; 95% CI 1.385-2.258) and omitting lymph nodes examination (HR 1.709; 95% CI 1.371-2.130) had lower CSS.ConclusionChemotherapy has different effects in patients with OCCC at different stages and ages. Age and lymph nodes examination may be factors that affect the outcome of patients with OCCC.

scholarly journals Clinical Characteristics and Prognosis of Ovarian Clear Cell Carcinoma: a Retrospective Study of 112 Patients in Beijing

2020 ◽  
Author(s):  
Huimei Zhou ◽  
Qian Liu ◽  
Xiaohua Shi ◽  
Jiaxin Yang ◽  
Dongyan Cao ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Cox Regression ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Stage I ◽  
Stage Iii ◽  
Ca 125 ◽  
Ovarian Clear Cell Carcinoma

Abstract ObjectivesThis retrospective study aimed to evaluate the clinical characteristics and prognosis of ovarian clear cell carcinoma (OCCC) and to further explore the monitoring value of cancer antigen 125 (CA-125).MethodsThe medical records of 112 OCCC patients who were treated in Peking Union Medical College Hospital (PUMCH) between 2014 and 2019 were collected and reviewed, and data such as age, Federation of Gynecology and Obstetrics (FIGO) stage, CA-125 level, treatment, recurrence, and death were extracted.OutcomesThe median patient age was 50 (45, 57) years. Sixty (53.57%) patients were in stage I, 13 (11.61%) patients were in stage II, 22 (28.57%) patients were in stage III, and 7 (6.25%) patients were in stage IV. In total, 109 (97.32%) patients received adjuvant chemotherapy. The median chemotherapy cycles of CA-125 normalization was 2 (0, 3). The 1-year and 3-year progression-free survival (PFS) rates were 87.85% and 72.90%, respectively. The median PFS1 duration was 19 (11, 35) months, and the median overall survival (OS) duration was 24 (13, 40) months. Recurrence occurred in 32 patients, of whom 7 (21.88%) developed platinum-resistant recurrence. Fifty percent of relapsed patients had a CA-125 level<35 IU/ml at the time of relapse. Nine (28.13%) patients experienced a second recurrence. In the multivariate Cox regression analysis, the Chemotherapy cycles of CA-125 normalization remained nonsignificant for stage I (P=0.003, HR 4.287, 95% CI=1.632–11.258) and stage III (P=0.003, HR 4.287, 95% CI=1.632–11.258) disease. Multivariate Cox regression showed that platinum resistance was an independent factor for PFS2 (P=0.008, HR 11.562, 95% CI=1.873–71.353).ConclusionsFIGO stage and chemotherapy resistance are independent risk factors for prognosis. CA-125 levels following treatment are a valid indicator for treatment monitoring. Regardless of chemosensitivity to CA-125, CA-125 normalization before chemotherapy cycle 2 may not be a distinct inflection point for PFS and OS.

Sign in / Sign up

Export Citation Format

Share Document